Etifoxine

DB08986ApprovedWithdrawnSmall molecule

Etifoxine is a benzoxazine class drug primarily used as an anxiolytic, but that also possesses neuroprotective, neuroplastic, and anti-inflammatory properties; these effects are thought to arise due to modulation of GABAergic neurotransmission and neurosteroid synthesis. Etifoxine is an anxiolytic and anticonvulsant drug developed by Hoechst in the 1960s.

Chemical structure of Etifoxine
Mechanism
Curator reviewed
Formula / weight
C17H17ClN2O · 300.79 g/mol (avg)
Code names
HOE 36801

Resolves to

Compound
UNIIX24X82MX4XCAS21715-46-8ChEMBLCHEMBL2106227ChEBI135272PubChem30768KEGGD07320
Clinical / RWD
RxNorm24441ATCN05BX03
Structure
InChIKeyIBYCYJFUEJQSMK-UHFFFAOYSA-NSMILESCCNC1=NC2=CC=C(Cl)C=C2C(C)(O1)C1=CC=CC=C1
Targets
P30536TSPO

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
667Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
2Marketed productsAcross 2 countries and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 7 drug categories
Sign in
10+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Etifoxine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In